Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Salvador Gámez Casado"'
Autor:
José Manuel Baena Cañada, Carlos de la Torre Hita, Marta Bernal Gómez, Alicia Campini Bermejo, Salvador Gámez Casado, Lourdes Rodríguez Pérez, Alicia Quílez Cutillas, Julio Calvete Candenas, Sara Estalella Mendoza, Encarnación Benítez Rodríguez
Publikováno v:
Archives of Breast Cancer (2021)
Background: There is a tendency to decrease the intensity of breast cancer treatments, e.g. omitting adjuvant chemotherapy in endocrine-sensitive and HER-2 negative patients. The purpose of this study was to analyse changes in the frequency of the in
Externí odkaz:
https://doaj.org/article/02b41ead8e914ccfb281281d854ff377
Autor:
José M. Baena-Cañada, Salvador Gámez-Casado, Lourdes Rodríguez-Pérez, Cristina Bandera-López, Andrés Mesas-Ruiz, Alicia Campini-Bermejo, Marta Bernal-Gómez, Manuel Zalabardo-Aguilar, Julio Calvete-Candenas, Gala Martínez-Bernal, Alicia Quílez-Cutillas, Lidia Atienza-Cuevas, Marcial García-Rojo, Encarnación Benítez-Rodríguez, Bella Pajares-Hachero, María José Bermejo-Pérez
Publikováno v:
Medicina Clínica. 159:351-358
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72cccd3f731ac8f736a5c553cf5b02d2
https://doi.org/10.1016/j.medcli.2021.11.008
https://doi.org/10.1016/j.medcli.2021.11.008
Autor:
Encarnación Benítez Rodríguez, Sara Estalella Mendoza, Lourdes Rodríguez Pérez, Carlos de la Torre Hita, Alicia Quílez Cutillas, José M. Baena Cañada, Alicia Campini Bermejo, Julio Calvete Candenas, Salvador Gámez Casado, Marta Bernal Gómez
Publikováno v:
Archives of Breast Cancer (2021)
Background: There is a tendency to decrease the intensity of breast cancer treatments, e.g. omitting adjuvant chemotherapy in endocrine-sensitive and HER-2 negative patients. The purpose of this study was to analyse changes in the frequency of the in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::977b9e4f1d3231bc6d2311772d0b3770
https://doi.org/10.32768/abc.202183233-242
https://doi.org/10.32768/abc.202183233-242
Autor:
Encarnación González Flores, Alicia Quílez Cutillas, Alejandro González, Salvador Gámez Casado, Marta Amérigo Góngora, Javier Salvador Bofill, Maria Carmen Álamo de la Gala, Carlos José Rodríguez González, Josefina Cruz Jurado, Pedro Sánchez Rovira, Rocío Urbano Cubero, Rocío Álvarez Ambite, Elisenda Llabrés Valenti, Maria Valero Arbizu, Fernando Henao Carrasco, Manuel Ruiz Borrego, Antonia Martínez Guisado
Publikováno v:
Cancer Research. 80:P1-18
Background: Pertuzumab (P) has been aproved in neoadjuvant setting for HER2 positive early breasta cancer patients in association with Trastuzumab (T) and chemotherapy. Diverse studies support this combination as NeoSphere, Tryphaena, GeparSepto or B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccc12970545b936fef593412d01ec64c
https://doi.org/10.1158/1538-7445.sabcs19-p1-18-29
https://doi.org/10.1158/1538-7445.sabcs19-p1-18-29
Autor:
José M. Baena Cañada, Salvador Gámez-Casado, Lourdes Rodríguez-Pérez, Cristina Bandera-López, Andrés Mesas-Ruiz, Alicia Campini-Bermejo, Marta Bernal-Gómez, Manuel Zalabardo-Aguilar, Julio Calvete-Candenas, Gala Martínez-Bernal, Alicia Quílez-Cutillas, Lidia Atienza-Cuevas, Marcial García-Rojo, Encarnación Benítez-Rodríguez, Bella Pajares-Hachero, María José Bermejo-Pérez
Publikováno v:
Medicina clinica. 159(8)
To identify subgroups with good progress over an extended period, we used diagnostic screening, tumour palpability, tumour phenotype, and node involvement.We identified patients with good progress by means of a descriptive, observational and retrospe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35c7f35070474af974776f6c5dc795dc
https://pubmed.ncbi.nlm.nih.gov/35181168
https://pubmed.ncbi.nlm.nih.gov/35181168
Autor:
Encarnación Benítez Rodríguez, Salvador Gámez Casado, Lourdes Rodríguez Pérez, Petra Rosado Varela, Sara Estalella Mendoza, Patricia Ramírez Daffós, Cristina Cortés Carmona, José M. Baena Cañada, Alicia Quílez Cutillas
Publikováno v:
Medicina Clínica. 151:469-475
Resumen Antecedentes y objetivos En el cancer de mama hormonosensible, HER-2 negativo, con ganglios negativos, la presencia de un riesgo genomico bajo permite tratar solo con hormonoterapia adyuvante, obteniendo unas excelentes tasas de supervivencia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2833704692d8d16eba005d5776cc726
https://doi.org/10.1016/j.medcli.2018.01.020
https://doi.org/10.1016/j.medcli.2018.01.020
Autor:
Salvador Gamez Casado, Javier David Benitez Fuentes, Beatriz Álvarez Rodríguez, Gema García Ledo
Publikováno v:
Respirology Case Reports, Vol 12, Iss 4, Pp n/a-n/a (2024)
Abstract Oncogene‐negative, PDL1‐negative metastatic non‐small cell lung cancer (NSCLC) presents significant treatment challenges due to its complexity and resistance to conventional therapies. The case report presented addresses a 55‐year‐
Externí odkaz:
https://doaj.org/article/39eeebcce12a4a34ba1b236acf2cafde
Autor:
Alicia Quílez Cutillas, Julio Calvete Candenas, Salvador Gámez Casado, José M. Baena-Cañada, Lourdes Rodríguez Pérez, Encarnación Benítez Rodríguez, María J. Martínez Bautista, Alicia Campini Bermejo
Publikováno v:
Journal of palliative medicine. 22(12)
Background: The most important decision after diagnosing terminal cancer is whether to provide active therapy or withhold treatment. Objective: To analyze the aggressiveness of care by eva...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaea976a4aed7f2f954beb2e24f2d89e
https://pubmed.ncbi.nlm.nih.gov/31184989
https://pubmed.ncbi.nlm.nih.gov/31184989
Autor:
Lourdes Rodríguez Pérez, Sara Estalella Mendoza, Patricia Ramírez Daffós, Encarnación Benítez Rodríguez, Petra Rosado Varela, Alicia Quílez Cutillas, Salvador Gámez Casado, José M. Baena Cañada, Cristina Cortés Carmona
Publikováno v:
Medicina clinica. 151(12)
Background and objectives In endocrine-sensitive, HER2 negative, node negative breast cancer, the presence of a low genomic risk allows treatment with adjuvant endocrine therapy alone, obtaining excellent survival rates. The justification for this st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62959af75e1099c22312956c3b1b0b65
https://pubmed.ncbi.nlm.nih.gov/29501438
https://pubmed.ncbi.nlm.nih.gov/29501438